CDNA (CareDx Health) Gross Return on Sales

Official company branding of CareDx Inc (CDNA)

CareDx, Inc (CDNA) generates revenue from genomic monitoring of transplanted organs. This gross profit margin chart visualizes this financial trend, where 70.50 shows the current value of the metric. However, Medicare regulatory pressure and competition create certain risks. Active developments in non-invasive bioinformatics and the launch of high-precision diagnostic systems support business stability.

CDNA - CareDx, Inc Return on Gross Profit over the range 07/04/2022 - 11/20/2026

Analytical breakdowns and data insights for company caredx.com (CDNA)

- stock value and consensus price forecast:
Fundamental valuation:CDNA, caredx.com
Mass-produced product of CareDx, Inc

Gross margin determines operational efficiency by measuring the profit share after deducting direct production costs, allowing investors to assess the business's ability to generate cash flow. For CareDx, Inc (CDNA), this metric reflects the high added value of its unique diagnostic tests and their integration into medical protocols, a trend clearly evidenced by the company's gross margin history.